Press release
Metastatic Liver Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Request a sample and discover the recent advances in Metastatic Liver Cancer Treatment Drugs @ Metastatic Liver Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Metastatic Liver Cancer Pipeline Report
* In October 2024: HepaRegeniX GmbH- The goal of this clinical trial is to learn if HRX215 is safe and tolerable in adults who have undergone surgical removal of metastatic tumor(s) due to colorectal carcinoma in the liver.
* In October 2024:- DualityBio Inc.- A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors. This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
* DelveInsight's Metastatic Liver Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Metastatic Liver Cancer treatment.
* The leading Metastatic Liver Cancer Companies such as Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim , and others.
* Promising Metastatic Liver Cancer Therapies such as ThermoDox Registered (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG Registered -1, AV-299, RO7119929, Tocilizumab , and others.
Find out more about Metastatic Liver Cancer Therapeutics Assessment @ Metastatic Liver Cancer Preclinical and Discovery Stage Products [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Liver Cancer Emerging Drugs Profile
* exoASO STAT6: Codiak BioSciences
exoASO Trademark -STAT6 is an exosome therapeutic candidate engineered using our engEx Trademark Platform to overexpress Codiak's novel protein scaffold, PTGFRN, to selectively target uptake in M2 polarized tumor-associated macrophages. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
* STP 705: Sirnaomics
STP705, is a dual TGF-Ss1/COX-2 inhibitor. TGF-Ss1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development. STP705 leverages our locally administered PNP formulation for direct administration to diseased tissue. STP705 has received U.S. orphan drug designation for the treatment of certain hepatocellular carcinomas and liver fibrosis, including: primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
* ONCR 177: Oncorus
ONCR-177, our lead product candidate, is an intratumorally administered Herpes Simplex Virus (HSV) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
Explore groundbreaking therapies and clinical trials in the Metastatic Liver Cancer Pipeline. Access DelveInsight's detailed report now! @ New Metastatic Liver Cancer Drugs [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic-Liver-Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Metastatic Liver Cancer Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Metastatic Liver Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Metastatic Liver Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Metastatic Liver Cancer Pipeline Report
* Coverage- Global
* Metastatic Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Metastatic Liver Cancer Companies- Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
* Metastatic Liver Cancer Therapies- ThermoDox Registered (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG Registered -1, AV-299, RO7119929, Tocilizumab, and others.
Get the latest on Metastatic Liver Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Metastatic Liver Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Metastatic-Liver-Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic-Liver-Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name :Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name :Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ONCR 177: Oncorus
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name :Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic-Liver-Cancer Key Companies
* Metastatic-Liver-Cancer Key Products
* Metastatic-Liver-Cancer- Unmet Needs
* Metastatic-Liver-Cancer- Market Drivers and Barriers
* Metastatic-Liver-Cancer- Future Perspectives and Conclusion
* Metastatic-Liver-Cancer Analyst Views
* Metastatic-Liver-Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-liver-cancer-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Liver Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3697024 • Views: …
More Releases from ABNewswire
3 Tons Rail Guided Vehicle with Roller Table for Workshop Handling
With its customized structural design, intelligent control technology, and high environmental adaptability, this equipment redefines the material flow mode between production lines in mold factories. Structurally, the RGV [https://www.bfbtransfercart.com/40-ton-heavy-load-rail-guided-cart-rgv-product/] adopts a box-beam frame to ensure heavy load stability, with overall dimensions of 3000*1200*600mm. The platform features an innovative concave layout, with a removable roller table installed centrally.
Image: https://ecdn6.globalso.com/upload/p/3198/image_other/2026-01/global-news-search-image-111-7.jpg
The roller dimensions are perfectly matched to various production lines, enabling integrated "seamless…
Behind the Brand: How Sichuan Jaguarsign Crafted the Complete Visual Identity fo …
Image: https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcTfI3yh3zN9dwx1QIcIjKeuyEM4gVTkE-z1MA&s
Fusiongyms Sign made by Jaguarsign
In the competitive world of the fitness industry, equipment is standard, but atmosphere is the differentiator. When you walk into a gym, what makes you want to stay? What makes you want to take a selfie and post it on Instagram? What makes you feel part of a community?
The answer is Branding.
At Sichuan Jaguarsign, we understand that signage is not just about showing people where…
CASE580 Wheel Hubs & Spindles - Industry Trends and Best Practices
Part No.: A66678, A66759 [https://www.tackmachinery.com/a66759/] 335132A1 [https://www.tackmachinery.com/335132a1/], 335130A1, D125341, D125340 [https://www.tackmachinery.com/products/]
For over a decade, we have been a leading and trusted manufacturer of premium-quality CASE580 Wheel Hubs [https://www.tackmachinery.com/products/] and Spindles. Our unwavering commitment to precision engineering, stringent quality control, and robust production capacity ensures every component meets the highest standards of durability and performance.
Our products have earned the lasting trust of a loyal customer base across Southeast Asia and South…
Beyond Food Storage: Why Every Modern Home Needs a Freeze Dryer in 2026
The Mainstream Shift to Food Autonomy
In 2026, continued inflation and supply uncertainty have pushed family food security mainstream. The home freeze dryer has evolved from a niche tool into an essential appliance for long-term autonomy and reducing food waste.
The 25-Year Advantage: Superior Preservation
Why are households switching from canning to freeze-drying? It comes down to unmatched quality and longevity over traditional methods:
True Longevity: Freeze-dried food processed in quality machines like the…
More Releases for Metastatic
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth?
The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
